Skip to main content
Premium Trial:

Request an Annual Quote

HCS Firm Cellumen Snags Series A Funding

NEW YORK, June 20 (GenomeWeb News) - PA Early Stage Partners, a family of venture funds based in Wayne, Penn., said today that it has made a Series A investment in high-content screening firm Cellumen.

 

Cellumen, based in Pittsburgh, measures proteins and RNA in cells using multiple high-content screening platforms along with several proprietary reagents. It was founded by Lansing Taylor, who also founded the high-content screening tool provider Cellomics.

 

The amount of the investment was not provided.

 

For further details on Cellumen's business model and strategy following the financing, see the June 13 issue of Cell-Based Assay News, a GenomeWeb News sister publication.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.